Winnow Wealth LLC Invests $962,000 in United Therapeutics Corporation $UTHR

Winnow Wealth LLC purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,972 shares of the biotechnology company’s stock, valued at approximately $962,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Darwin Global Management Ltd. bought a new position in shares of United Therapeutics during the 3rd quarter valued at $317,617,000. Norges Bank bought a new stake in United Therapeutics in the 4th quarter worth $293,418,000. Baillie Gifford & Co. bought a new stake in United Therapeutics in the 4th quarter worth $157,390,000. UBS Group AG grew its holdings in United Therapeutics by 45.3% in the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after acquiring an additional 70,445 shares during the last quarter. Finally, Soleus Capital Management L.P. grew its holdings in United Therapeutics by 35.0% in the 2nd quarter. Soleus Capital Management L.P. now owns 209,794 shares of the biotechnology company’s stock worth $60,284,000 after acquiring an additional 54,400 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $9,956,712.48. This trade represents a 34.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 624,043 shares of company stock worth $351,930,785. Company insiders own 8.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on UTHR shares. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Cantor Fitzgerald raised their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Oppenheimer raised their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a report on Thursday, May 7th. Finally, UBS Group raised their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Trading Down 0.9%

NASDAQ:UTHR opened at $544.69 on Tuesday. The company has a 50-day moving average price of $568.47 and a 200-day moving average price of $519.64. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The stock has a market cap of $23.12 billion, a price-to-earnings ratio of 20.11, a P/E/G ratio of 1.79 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same period in the prior year, the business posted $6.63 earnings per share. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. Equities analysts forecast that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.